Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect

Peptides

Volumn 30, Issue 12, 2009, Pages 2286-2291

  Huang, Cong Xin ^a   Yuan, Ming Jie ^a   Huang, He ^a   Wu, Gang ^a   Liu, Yu ^a   Yu, Sheng Bo ^a   Li, Hai Tao ^a   Wang, Tao ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Ghrelin; Matrix metalloproteinase; Myocardial infarction; Pro inflammatory cytokines

Indexed keywords

GELATINASE A; GELATINASE B; GHRELIN; INTERLEUKIN 1BETA; MESSENGER RNA; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; NONHUMAN; PRIORITY JOURNAL; RAT; SCAR FORMATION; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GHRELIN; IN SITU NICK-END LABELING; INTERLEUKIN-1BETA; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

RATTUS;

EID: 70449656984     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.09.004     Document Type: Article

References (36)

1. Baldanzi G., Filigheddu N., Cutrupi S., Catapano F., Bonissoni S., Fubini A., et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. Journal of Cell Biology 159 (2002) 1029-1037
2. Deschamps A.M., and Spinale F.G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovascular Research 69 (2006) 666-676
3. Deten A., Volz H.C., Briest W., and Zimmer H.G. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovascular Research 55 (2002) 329-340
4. Diwan A., Dibbs Z., Nemoto S., DeFreitas G., Carabello B.A., Sivasubramanian N., et al. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation 109 (2004) 262-268
5. Dixit V.D., Schaffer E.M., Pyle R.S., Collins G.D., Sakthivel S.K., Palaniappan R., et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. Journal of Clinical Investigation 114 (2004) 57-66
6. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. Journal of Clinical Investigation 106 (2000) 55-62
7. Ertl G., and Frantz S. Healing after myocardial infraction. Cardiovascular Research 66 (2005) 22-32
8. Francis J., Weiss R.M., Johnson A.K., and Felder R.B. Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 284 (2003) R328-R335
9. Francis J., Zhang Z.H., Weiss R.M., and Felder R.B. Neural regulation of the proinflammatory cytokine response to acute myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology 287 (2004) H791-H797
10. Hayashidani S., Tsutsui H., Ikeuchi M., Shiomi T., Matsusaka H., Kubota T., et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology 285 (2003) H1229-H1235
11. Ingelsson E., Arnlov J., Sundstrom J., and Lind L. Inflammation, as measured by the erythrocyte sedimentation rate, is an independent predictor for the development of heart failure. Journal of the American College of Cardiology 45 (2005) 1802-1806
12. Katergari S.A., Milousis A., Pagonopoulou O., Asimakopoulos B., and Nikolettos N.K. Ghrelin in pathological conditions. Endocrine Journal 55 (2008) 439-453
13. Kawamura N., Kubota T., Kawano S., Monden Y., Feldman A.M., Tsutsui H., et al. Blockade of NF-kappa B improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. Cardiovascular Research 66 (2005) 520-529
14. Kawano S., Kubota T., Monden Y., Tsutsumi T., Inoue T., Kawamura N., et al. Blockade of NF-kappa B improves cardiac function and survival after myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology 291 (2006) H1337-H1344
15. Kelly D., Cockerill G., Ng L.L., Thompson M., Khan S., Samani N.J., et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. European Heart Journal 28 (2007) 711-718
16. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
17. Li W.G., Gavrila D., Liu X.B., Wang L.X., Gunnlaugsson S., Stoll L.L., et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappa B activation in human endothelial cells. Circulation 109 (2004) 2221-2226
18. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25 (2001) 402-408
19. Mountain D.J.H., Singh M., Menon B., and Singh K. Interleukin-1 beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKC alpha/beta(1) and MAPKs. American Journal of Physiology-Cell Physiology 292 (2007) C867-C875
20. Mukherjee R., Mingoia J.T., Bruce J.A., Austin J.S., Stroud R.E., Escobar G.P., et al. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology 291 (2006) H2216-H2228
21. Nagaya N., and Kangawa K. Therapeutic potential of ghrelin in the treatment of heart failure. Drugs 66 (2006) 439-448
22. Nagaya N., Moriya J., Yasumura Y., Uematsu M., Ono F., Shimizu W., et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110 (2004) 3674-3679
23. Nagaya N., Uematsu M., Kojima M., Ikeda Y., Yoshihara F., Shimizu W., et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104 (2001) 1430-1435
24. Nian M., Lee P., Khaper N., and Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circulation Research 94 (2004) 1543-1553
25. Orn S., Manhenke C., Squire I.B., Ng L., Anand I., and Dickstein K. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: Relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. Journal of Cardiac Failure 13 (2007) 843-849
26. Pfeffer M.A., Pfeffer J.M., Fishbein M.C., Fletcher P.J., Spadaro J., Kloner R.A., et al. Myocardial infarct size and ventricular function in rats. Circ Res 44 (1979) 503-512
27. Sakata Y., Yamamoto K., Mano T., Nishikawa N., Yoshida J., Hori M., et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 109 (2004) 2143-2149
28. Siwik D.A., and Colucci W.S. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Failure Reviews 9 (2004) 43-51
29. Spinale F.G., Escobar G.P., Hendrick J.W., Clark L.L., Camens S.S., Mingoia J.P., et al. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: Differential effects on short and long-term survival. Journal of Pharmacology and Experimental Therapeutics 318 (2006) 966-973
30. Sun M., Dawood F., Wen W.H., Chen M.Y., Dixon I., Kirshenbaum L.A., et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110 (2004) 3221-3228
31. Tao Z.Y., Cavasin M.A., Yang F., Liu Y.H., and Yang X.P. Temporal changes in matrix metalloproteinase expression and inflammatory response associated with cardiac rupture after myocardial infarction in mice. Life Sciences 74 (2004) 1561-1572
32. Timmers L., van Keulen J.K., Hoefer I.E., Meijs M.F.L., van Middelaar B., den Ouden K., et al. Targeted deletion of nuclear factor kappa B p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circulation Research 104 (2009) 699-706
33. Wilson E.M., Moainie S.L., Baskin J.M., Lowry A.S., Deschamps A.M., Mukherjee R., et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 107 (2003) 2857-2863
34. Xie Z.L., Singh M., and Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1 beta. Journal of Biological Chemistry 279 (2004) 39513-39519
35. Xu X.B., Pang J.J., Cao J.M., Ni C., Xu R.K., Peng X.Z., et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. American Journal of Physiology-Heart and Circulatory Physiology 289 (2005) H1643-H1651
36. Yoshiyama M., Takeuchi K., Omura T., Kim S., Yamagishi H., Toda I., et al. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension 33 (1999) 961-968